white-skin-privileged child of Mexican immigrant shot dead in the head Saturday:

Trump voters are not all as crazy as he is. It's a subset that are chaos agents.

But hey keep mocking Trump voters if it makes you feel good.

By Jordain Carney @ TheHill.com - 01/19/22 08:57 PM EST

[....] Senators voted 49-51, falling short of 60 votes needed to advance the legislation.

The vote will trigger an attempt by Senate Majority Leader Charles Schumer (D-N.Y.) to change the Senate’s rules to get rid of the 60-vote hurdle for voting rights legislation, while leaving it in place for other issues.   [....]

Though Schumer picked up a key holdout on Wednesday morning when Sen. Mark Kelly (D-Ariz.), who is up for reelection in 2022, said that he would support the rules change, Sens. Joe Manchin (D-W.Va.) and Kyrsten Sinema (D-Ariz.) remain opposed to the change [....]

Under the proposed rules change, Democrats would enact a talking filibuster for voting rights legislation. That would allow opponents to delay a bill by holding the Senate floor, but the legislation would be able to pass the Senate by a simple majority.  

Democrats had discussed trying to change the rules to shift to a talking filibuster for all legislation, but negotiators said they limited the proposal to just voting legislation to try to shore up support within the caucus. 

The rules-change vote is expected to take place as soon as Wednesday night, though Democrats have cautioned that it could slip into Thursday [....]

Yes, it relates to the court case in Texas

Here's a good response to a perhaps FUD paper on tele-abortion submitted by a doctor at a Christian clinic that offers no contraception or birth control assistance:
==
In Reply: Several important studies have been published on this topic recently. We appreciate the opportunity to share more information on the safety and effectiveness of providing mifepristone without in-person testing or ultrasonography. In a cohort study of 54,142 women in Great Britain, the rate of serious adverse events in 18,435 women who had a no-test telemedicine abortion between April and June 2020 (0.04%) was no different than in patients who received traditional in-person care (P = .56).1 In another study, family physicians in the United States successfully provided medication abortion to more than 500 women using an asynchronous telehealth platform, with 90% meeting criteria for no-test abortion care.2

On April 12, 2021, the FDA announced its intention “...to exercise enforcement discretion with respect to the in-person dispensing requirement of the Mifepristone REMS Program, ...during the COVID-19 public health emergency” as a “...result of a thorough scientific review by experts within FDA's Center for Drug Evaluation and Research (CDER), who evaluated relevant information, including available clinical outcomes data and adverse event reports.”3

Mifepristone is one of the most carefully studied medications that has been brought to market. Although the article by Aultman, et al., describes the breakdown of the types of reported adverse events, it does not include the denominator of mifepristone use since FDA approval in 2000.4 Over the past 20 years, mifepristone has been used for medication abortion by more than 2.75 million people, and there have been only 24 deaths, meaning that the risk of death is less than one in 100,000.4 Similarly, in considering the overall 5.2% complication rate after medication abortion reported by Upadhyay, et al., it is important to note that 94% of the documented complications were minor issues; the rate of major complications was 0.31 per 100 abortions. These rates of complications are far lower than rates associated with term delivery and indicate that mifepristone is safer than over-the-counter acetaminophen, which causes 500 deaths per year in the United States.5,6

Honor MacNaughton, MD
Boston, Mass.
Email: [it's there if you want to google it]

Melissa Nothnagle, MD, MSc
Salinas, Calif.

Jessica Early, MD
Boston, Mass.

Author disclosure: No relevant financial affiliations.

By Thomas Edsall @ NYTimes.com, Jan. 5